Randomized trial demonstrates no improvement in clinical outcomes with darbepoetin alfa in systolic heart failure and mild-to-moderate anemia, indicating its lack of benefit.
Treatment with darbepoetin alfa did not improve clinical outcomes in patients with systolic heart failure and mild-to-moderate anemia. Our findings do not support the use of darbepoetin alfa in these patients. (Funded by Amgen; RED-HF ClinicalTrials.gov number, NCT00358215.).
No takes yet. Share an insight, caveat, or question.
Swedberg et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: